Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 349

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 349
---
2023                       |     | $       | - |     | $       | - |     | $       |  610,381 |   |     | $     |  610,381 |   |
| Loss on revaluation of warrant liability         |     |         | - |     |         | - |     |         |   36,657 |   |     |       |   36,657 |   |
| Balance at March 31, 2023                        |     |         | - |     |         | - |     |         |  647,038 |   |     |       |  647,038 |   |
| Gain on revaluation of warrant liability         |     |         | - |     |         | - |     |         | (261,822 | ) |     |       | (261,822 | ) |
| Balance at June 30, 2023                         |     | $       | - |     | $       | - |     | $       |  385,216 |   |     | $     |  385,216 |   |
| Gain on revaluation of warrant liability         |     |         | - |     |         | - |     |         | (186,067 | ) |     |       | (186,067 | ) |
| Balance at September 30, 2023                    |     | $       | - |     | $       | - |     | $       |  199,149 |   |     | $     |  199,149 |   |

<div align='center'>F-23</div>

NOTE 10 – STOCK-BASED COMPENSATION

In October 2016, Predecessor’s Board of
Directors approved the adoption of an Equity Incentive Plan (“Predecessor EIP”). As amended, the Predecessor EIP permits
Predecessor to grant awards allowing for the issuance of up to 4,888,402 shares of Predecessor’s common stock. On close of the
Merger, outstanding awards issued for the Predecessor EIP were converted to options to purchase a number of shares of the Company’s
Common Stock equal to the number of Predecessor shares multiplied by the Merger conversion ratio of 0.064452 at a price of the Predecessor
option strike price divided by the Merger conversion ratio. The Predecessor EIP was then cancelled.

Pre